Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including twenty-three which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Array BioPharma (ARRY); Unity Biotechnology (UBX); Hua Medicine (2552:HK); Karuna Therapeutics (KRTX); Vir Biotechnology; Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL; Gossamer Bio (GOSS); Ikaria; Kythera Biopharmaceuticals (KYTH); Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics (RUBY); Syros Pharmaceuticals (SYRS); Sana Biotechnology; KSQ Therapeutics; Beam Therapeutics; NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Fate Therapeutics (FATE); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Editas (EDIT); 10x Genomics; Semma Therapeutics; IDUN Pharmaceuticals; Classmates.com; Sienna Biopharmaceuticals (SNNA); Fate Therapeutics (FATE); WuxiNextCODE; and Everyday Learning Corporation.
Mr. Nelsen is a director of Vir Bio, GRAIL, Sana Biotechnology, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.